Track record · closed signal

Stoke Therapeutics, Inc. (STOK) — closed signal from January 22, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on April 22, 2026 — +19% at the close.

Predicted vs. what happened

STOK price · publication thesis → realized outcomesplit-adjusted

$30.50 – $27.80Entry zone — fair-value band

$30.16Published — price the day we called it

$36.19Target — the price the thesis aimed for

$40.22Peak — highest point inside the window, not a realized return

$35.90Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 32 days.

At window close

+19%

realized, from the publication price to the last close inside the window

Peak gain

+33.4%

peak, from the publication price — not a realized return

S&P 500, same window

+3.5%

SPY over the identical days, dividend-adjusted

Window close

$35.90

last close inside the window, ended April 22, 2026

Peak price

$40.22

peak on March 10, 2026 — not a realized return

Days to target

The thesis — published January 22, 2026

Predicted growth

+20%

over the measurement window

Target price

$36.19

the price the thesis aimed for

Entry zone

$30.50 – $27.80

the fair-value band we waited for

Price at publication

$30.16

published January 22, 2026

Confidence

80%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Stoke looks like a short-term rebounding biotech: selling pushed the stock down, but clear trial timelines and a mid-2027 data readout give a visible path for the stock to recover if sentiment improves. Buy in stages inside the zone and aim for a return toward the prior trading area. Main danger is biotech volatility or bad trial or regulatory news.

Primary drivers

Clear Phase 3 timeline keeps upcoming news visible
Recent heavy selling could lead to a quick rebound
Events and conferences can bring specialist buyers back
Stock swings more, so it can rise faster if risk appetite returns

How it played out

STOK: target reached in 32 days

Lyra published STOK at $30.16 on 2026-01-22 with a short-term thesis for 20% growth toward $36.19. The thesis pointed to a clear Phase 3 timeline, recent heavy selling, events and conferences, and the stock's higher swing profile as reasons a rebound could happen if sentiment improved.

Inside the window, STOK rose above the target. It peaked at $40.22 on 2026-03-10, with a 33.4% gain, and reached the target in 32 days. It ended the window at $35.90 on 2026-04-22. The thesis played out.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All STOK signals